China SXT Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
China SXT Pharmaceuticals, Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec 2025Mar 2024Mar 2023Mar 2022Mar 2021
Revenue & Gross Profit
Revenue1.741.931.972.604.78
Cost of Revenue1.371.371.551.351.94
Gross Profit0.370.550.431.252.84
Operating Expenses
Research & Development0.190.000.000.000.00
Selling, General & Administrative3.052.655.686.445.04
Operating Expenses3.052.655.686.445.04
Operating Income-2.68-2.09-5.26-5.19-2.20
Other Income/Expense
Interest Income0.000.010.000.000.01
Interest Expense0.65-0.55-0.48-0.04-1.12
Other Income/Expense-0.62-0.040.15-0.180.36
Income
Income Before Tax-3.30-3.10-5.93-5.41-2.94
Income Tax Expense0.000.000.000.33-0.19
Net Income-3.30-3.10-5.93-5.74-2.75
Net Income - Continuous Operations-3.30-3.10-5.93-5.740.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-2.57-1.89-5.01-4.87-1.85
EBIT-2.66-2.09-5.26-5.19-2.20
Depreciation & Amortization0.080.200.250.320.35
Earnings Per Share
Basic EPS-8.00-29.00-178.00-85613.00-
Diluted EPS-8.00-29.00-178.00-85613.00-
Basic Shares Outstanding0.400.110.030.000.00
Diluted Shares Outstanding0.400.110.030.000.00